Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 1.00 |
| ▸ | ABL1 | P00519 | 14/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 12/20 | 1.00 |
| ▸ | HCK | P08631 | 6/20 | 1.00 |
| ▸ | FRK | P42685 | 6/20 | 1.00 |
| ▸ | BLK | P51451 | 6/20 | 1.00 |
| ▸ | FYN | P06241 | 10/20 | 0.76 |
| ▸ | LYN | P07948 | 7/20 | 0.76 |
| ▸ | LCK | P06239 | 5/20 | 0.76 |
| ▸ | YES1 | P07947 | 8/20 | 0.69 |
| ▸ | FGR | P09769 | 8/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258366 | 0.88 | SRC (0.79) | SRCABL1PTK6HCKFRK | |
| SCHEMBL18258359 | 0.87 | SRC (1.00) | SRCABL1PTK6HCKFRK | |
| SCHEMBL18258333 | 0.87 | SRC (1.00) | SRCABL1PTK6HCKFRK | |
| SCHEMBL20132570 | 0.85 | SRC (0.82) | SRCABL1PTK6HCKFRK | |
| SCHEMBL20132627 | 0.82 | SRC (0.77) | SRCABL1PTK6HCKFRK | |
| SCHEMBL20132576 | 0.82 | SRC (1.00) | SRCABL1PTK6HCKFRK | |
| SCHEMBL29381545 | 0.81 | ABL1 (1.00) | SRCABL1PTK6HCKFRK | |
| SCHEMBL18258375 | 0.81 | ABL1 (1.00) | SRCABL1PTK6HCKFRK | |
| SCHEMBL18258363 | 0.81 | SRC (0.83) | SRCABL1PTK6HCKFRK | |
| SCHEMBL18258362 | 0.81 | SRC (0.77) | SRCABL1PTK6HCKFRK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849050-B | Compound (I) | 爱丁堡大学董事会 | 2020-10-13 | — | — | CN | disclosed |
| US-10294227-B2 | Compounds | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180127422-A1 | COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2018-05-10 | — | — | US | disclosed |
| WO-2016185160-A1 | COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127422-A1 | COMPOUNDS | CBR3, OR10J3, CBR1 | SRC 3282/4885ABL1 269/4885PTK6 3653/4885 |
| US-10294227-B2 | Compounds | CBR3, OR10J3, CBR1 | SRC 2785/4885ABL1 204/4885PTK6 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.